Confronto
DSIP vs. Octreotide
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
62568-57-4
83150-76-9
Peso molecolare
848.81 g/mol
1019.24 g/mol
Emivita
0.1 h
1.7 h
Sequenza
Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-GluD-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr(ol)Meccanismo d'azione
DSIP
DSIP was described in 1977 by the Schoenenberger-Monnier group in Basel as a blood-borne substance reported to induce EEG changes similar to delta sleep in animal models. The exact mechanism remains undefined to this day: no defined receptor, proposed modulation of opioid, GABAergic and glutamatergic systems. Most mechanistic findings stem from preclinical studies of the 1980s and 1990s and were later subjected to contested replication attempts.
Octreotide
Octreotide is a cyclic octapeptide that selectively binds somatostatin-receptor subtypes SSTR2 and SSTR5. Via G-protein-coupled signalling, adenylyl cyclase is inhibited, reducing the secretion of multiple hormones (growth hormone, IGF-1, glucagon, insulin, VIP, serotonin). Structural stabilisation via a disulfide bridge and D-amino acids extends the half-life relative to natural somatostatin (minutes to several hours).
Base di evidenze
Evidenza più alta
Studio sull'uomo
RCT sull'uomo
Studi
4
5
di cui sull'uomo
1
4
Effetti registrati
3
3
Contraddizioni aperte
1
1
Eventi avversi documentati
1
2
Stato legale
Voci complete
Frequently asked questions
- What is the difference between DSIP and Octreotide?
- DSIP is classified as "Ricerca (altro)", while Octreotide is classified as "Ricerca (altro)". DSIP: Synthetic nonapeptide isolated in 1977 by Guido Monnier and Marcel Schoenenberger from the blood of rabbits in delta sleep. Despite the name, the role in sleep regulation is contested and not confirmed by Western RCTs in larger populations. Octreotide: Synthetic octapeptide somatostatin analog with a longer half-life than endogenous somatostatin. FDA- and EMA-approved since the 1980s for acromegaly and neuroendocrine tumours. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, DSIP or Octreotide?
- The highest available evidence level is "Studio sull'uomo" for DSIP and "RCT sull'uomo" for Octreotide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of DSIP and Octreotide in Germany and the United States?
- Germania: DSIP — Non approvato, Octreotide — Su prescrizione. Stati Uniti: DSIP — Non approvato, Octreotide — Su prescrizione. These are factual summaries with source and review date on the individual pages.